### **The Tropical Disease Initiative**

# Comparative docking on protein structure models from ten tropical disease genomes.



http://bioinfo.cipf.es/squ/





# Need is High in the Tail

DALY Burden Per Disease in Developed CountriesDALY Burden Per Disease in Developing Countries



Disease data taken from WHO, <u>World Health Report 2004</u> DALY - Disability adjusted life years

DALY is not a perfect measure of market size, but is certainly a good measure for importance.

DALYs for a disease are the sum of the years of life lost due to premature mortality (YLL) in the population and the years lost due to disability (YLD) for incident cases of the health condition. The DALY is a health gap measure that extends the concept of potential years of life lost due to premature death (PYLL) to include equivalent years of 'healthy' life lost in states of less than full health, broadly termed disability. One DALY represents the loss of one year of equivalent full health.

# Need is High in the Tail

DALY Burden Per Disease in Developed CountriesDALY Burden Per Disease in Developing Countries



Disease data taken from WHO, <u>World Health Report 2004</u> DALY - Disability adjusted life years

DALY is not a perfect measure of market size, but is certainly a good measure for importance.

DALYs for a disease are the sum of the years of life lost due to premature mortality (YLL) in the population and the years lost due to disability (YLD) for incident cases of the health condition. The DALY is a health gap measure that extends the concept of potential years of life lost due to premature death (PYLL) to include equivalent years of 'healthy' life lost in states of less than full health, broadly termed disability. One DALY represents the loss of one year of equivalent full health.

## "Unprofitable" Diseases and Global DALY (in 1000's)

Malaria*	46,486	Trichuriasis	1,006		
Tetanus	7,074	Japanese encephalitis	709		
Lymphatic filariasis*	5,777	Chagas Disease*	667		
Syphilis	4,200	Dengue*	616		
Trachoma	2,329	Onchocerciasis*	484		
Leishmaniasis*	2,090	Leprosy*	199		
Ascariasis	1,817	Diphtheria	185		
Schistosomiasis*	1,702	Poliomyelitise	151		
Trypanosomiasis*	1,525	Hookworm disease	59		

Disease data taken from WHO, World Health Report 2004

DALY - Disability adjusted life year in 1000's.

\* Officially listed in the WHO Tropical Disease Research disease portfolio.

### Predicting binding sites in protein structure models.





# **Comparative docking**



## **DBAliv2.0** database

#### http://www.dbali.org



- ✓ Fully-automatic
- ✓ Data is kept up-to-date with PDB releases
- ✓ Tools for "on the fly" classification of families.
- ✓ Easy to navigate
- ✓ Provides tools for structure analysis

### Does not provide a stable classification similar to that of CATH or SCOP

Pairwise structure alignments						
Last update:	October 6th, 2007					
Number of chains:	96,804					
Number of structure-structure comparisons:*	1,748,371,897					
Multiple structure alignments						
Last update:	August 1st, 2007					
Number of representative chains:	34,637					
Number of families:	12,732					

#### Uses MAMMOTH for similarity detection

- ✓ VERY FAST!!!
- ✓ Good scoring system with significance

Ortiz AR, (2002) Protein Sci. 11 pp2606 Marti-Renom et al. 2001. Bioinformatics. 17, 746

## DBAliv2.0 database

http://www.dbali.org



Marti-Renom et al. BMC Bioinformatics (2007) Volume 8. Suppl S4

#### AnnoLyze

# Method



Inherited ligands: 4							
Ligand	Av. binding site seq. id.	Av. residue conservation	Residues in predicted binding site (size proportional to the local conservation)				
<u>MO2</u>	59.03	<u>0.185</u>	48 49 52 62 63 66 67 113 116				
CRY	20.00	<u>0.111</u>	23 29 31 37 44 48 49 83 85 94 96 103 121				
<u>80G</u>	20.00	<u>0.111</u>	19 20 21 48 49 51 96 98 136				
<u>ACY</u>	15.87	<u>0.163</u>	23 29 31 37 44 45 81 83 85 94 96 98 103 121 135				







# Benchmark

	Number of chains
Initial set*	78,167
LigBase**	30,126
Non-redundant set***	4,948 (8,846 ligands)

\*all PDB chains larger than 30 aminoacids in length (8th of August, 2006) \*\*annotated with at least one ligand in the LigBase database

\*\*\*not two chains can be structurally aligned within 3A, superimposing more than 75% of their Ca atoms, result in a sequence alignment with more than 30% identity, and have a length difference inferior to 50aa

	Optimal cut-off	Precision (%)					
Ligands	30%	71.9	13.7				
Sensitivity = $\frac{TP}{TP + FN}$ Precision = $\frac{TP}{TP + FP}$ ~90-95% of residues correctly predicted							

# **Modeling Genomes**

data from models generated by ModPipe (Eswar, Pieper & Sali)



A good model has MPQS of 1.0 or higher

# **Summary table**

#### models with inherited ligands

## 29,271 targets with good models, 297 inherited a ligand/substance similar to a known drug in DrugBank

	Transcripts	Modeled targets	Selected models	Inherited ligands	Similar to a drug	Drugs
C. hominis	3,886	1,614	666	197	20	13
C. parvum	3,806	1,918	742	232	24	13
L. major	8,274	3,975	١,409	478	43	20
M. leprae	١,605	1,178	893	310	25	6
M. tuberculosis	3,991	2,808	1,608	365	30	10
P. falciparum	5,363	2,599	818	284	28	13
P. vivax	5,342	2,359	822	268	24	13
T. brucei	7,793	1,530	300	138	13	6
T. cruzi	19,607	7,390	3,070	769	51	28
T. gondii	9,210	3,900	I,386	458	39	21
TOTAL	68,877	29,271	11,714	3,499	297	143

### L. major Histone deacetylase 2 + Vorinostat

Template 1t64A a human HDAC8 protein.



PDB	60	Template	000	Model	¢	Ligand	Exact	SupStr	SubStr	Similar
1c3sA	83.33/80.00	1t64A	36.00/1.47	LmjF21.0680.1.pdb	90.91/100.00	SHH	DB02546	DB02546	DB02546	DB02546



#### DB02546 Vorinostat

Small Molecule; Approved; Investigational

#### Drug categories:

Anti-Inflammatory Agents, Non-Steroidal Anticarcinogenic Agents Antineoplastic Agents Enzyme Inhibitors



For the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.

## L. major Histone deacetylase 2 + Vorinostat

Literature

Proc. Natl. Acad. Sci. USA Vol. 93, pp. 13143–13147, November 1996 Medical Sciences

## Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase

(cyclic tetrapeptide/Apicomplexa/antiparasitic/malaria/coccidiosis)

Sandra J. Darkin-Rattray<sup>\*†</sup>, Anne M. Gurnett<sup>\*</sup>, Robert W. Myers<sup>\*</sup>, Paula M. Dulski<sup>\*</sup>, Tami M. Crumley<sup>\*</sup>, John J. Allocco<sup>\*</sup>, Christine Cannova<sup>\*</sup>, Peter T. Meinke<sup>‡</sup>, Steven L. Colletti<sup>‡</sup>, Maria A. Bednarek<sup>‡</sup>, Sheo B. Singh<sup>§</sup>, Michael A. Goetz<sup>§</sup>, Anne W. Dombrowski<sup>§</sup>, Jon D. Polishook<sup>§</sup>, and Dennis M. Schmatz<sup>\*</sup>

Departments of \*Parasite Biochemistry and Cell Biology, <sup>‡</sup>Medicinal Chemistry, and <sup>§</sup>Natural Products Drug Discovery, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2004, p. 1435–1436 0066-4804/04/\$08.00+0 DOI: 10.1128/AAC.48.4.1435–1436.2004 Copyright © 2004, American Society for Microbiology. All Rights Reserved. Vol. 48, No. 4

#### Antimalarial and Antileishmanial Activities of Aroyl-Pyrrolyl-Hydroxyamides, a New Class of Histone Deacetylase Inhibitors

### P. falciparum tymidylate kinase + zidovudine

#### Template 3tmkA a yeast tymidylate kinase.



PDB	60	Template	666	Model	G	Ligand	Exact	SupStr	SubStr	Similar
2tmkB	100.00/100.00	3tmkA	41.00/1.49	PFL2465c.2.pdb	82.61/100.00	ATM		DB00495		DB00495



### DB00495 Zidovudine

Small Molecule; Approved

Drug categories:

Anti-HIV Agents

Antimetabolites

Nucleoside and Nucleotide Reverse Transcriptase

Inhibitors

Drug indication:

For the treatment of human immunovirus (HIV) infections.

N=N1

### P. falciparum tymydilate kinase + zidovudine

#### NMR Water-LOGSY experiments



# **TDI's kernel**

### http://tropicaldisease.org/kernel



## **Acknowledgments**

http://tropicaldisease.org
http://thesynapticleap.org

COMPARATIVE MODELING Andrej Sali M. S. Madhusudhan Narayanan Eswar Min-Yi Shen Ursula Pieper Ben Webb Maya Topf (Birbeck College)

MODEL ASSESSMENT David Eramian Min-Yi Shen Damien Devos

**FUNCTIONAL ANNOTATION** Andrea Rossi (Rinat-Pfizer) Fred Davis (Janelia Fram)

#### FUNDING

Prince Felipe Research Center Ministerio de Educación y Ciencia STREP UE Grant Marie Curie Reintegration Grant **MODEL ASSESSMENT** Francisco Melo (CU) Alejandro Panjkovich (CU)

NMR Antonio Pineda-Lucena Leticia Ortí Rodrigo J. Carbajo

MAMMOTH Angel R. Ortiz

**FUNCTIONAL ANNOTATION** Fatima Al-Shahrour Joaquin Dopazo

#### BIOLOGY

Jeff Friedman (RU) James Hudsped (RU) Partho Ghosh (UCSD) Alvaro Monteiro (Cornell U) Stephen Krilis (St.George H)



Tropical Disease Initiative Stephen Maurer (UC Berkeley) Arti Rai (Duke U) Andrej Sali (UCSF) Ginger Taylor (TSL) Matthew Todd (U Sydney)

CCPR Functional Proteomics Patsy Babbitt (UCSF) Fred Cohen (UCSF) Ken Dill (UCSF) Tom Ferrin (UCSF) John Irwin (UCSF) Matt Jacobson (UCSF) Tack Kuntz (UCSF) Andrej Sali (UCSF) Brian Shoichet (UCSF) Chris Voigt (UCSF)

#### EVA

Burkhard Rost (Columbia U) Alfonso Valencia (CNB/UAM)

#### CAMP

Xavier Aviles (UAB) Hans-Peter Nester (SANOFI) Ernst Meinjohanns (ARPIDA) Boris Turk (IJS) Markus Gruetter (UE) Matthias Wilmanns (EMBL) Wolfram Bode (MPG)